Impact of severe OSA on pharmacoinvasive treatment in ST elevation myocardial infarction patients
- 4 Downloads
The negative association between obstructive sleep apnea (OSA) and adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention (PCI) is well documented. However, little is known about the influence of OSA on fibrinolytic therapy. The aim of this study was to evaluate the impact of severe OSA on pharmacoinvasive treatment in ST elevation myocardial infarction (STEMI) patients.
We enrolled consecutive STEMI patients without previous vascular disease, heart failure, or OSA diagnosis. All patients underwent either a pharmacoinvasive therapy or primary PCI. Syntax score (SS) was calculated for all patients, and a full bedside polysomnography was performed in the first 72 h of admission. In-hospital events and 30 days readmissions were analyzed.
The sample included 116 patients, 87 men. Patients with severe OSA were older (p = 0.01), had higher neck and abdominal circumferences (p < 0.01), and had higher BMI (p < 0.01). They also had lower reperfusion rates post-fibrinolysis (20 vs. 65%; p = 0.001), higher SS (20.2 ± 11.2 vs. 14.6 ± 10.6; p = 0.03), lower left ventricle ejection fraction (45 ± 8 vs. 51 ± 10%; p = 0.02), and a higher incidence of atrial arrhythmias (4 vs. 21%; p = 0.02). STEMI patients with severe OSA presented with threefold increase in the risk for at least one adverse outcome. Regression analysis showed that both severe OSA and hypertension were independent predictors of higher SS.
Severe OSA was associated with a poor outcome after pharmacoinvasive treatment in STEMI patients.
KeywordsObstructive sleep apnea Fibrinolysis Acute coronary syndrome
This study was supported by the Associação Fundo de Incentivo à Pesquisa (AFIP), which provided personnel and the polysomnographic systems used during data collection.
This study was funded by the Associação Fundo de Pesquisa em psicofarmacologia (AFIP/2016).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
- 9.Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O’Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, UKA S, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Council on Epidemiology and Prevention, Statistics Committee and Stroke Statistics Subcommittee (2018) Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 137(12):e67–e492CrossRefGoogle Scholar
- 11.Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Antman EM, Cannon CP, Gibson CM (2006) Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 114(19):2019–2025PubMedCrossRefGoogle Scholar
- 12.Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, Miller DP, Henry TD, Gibson CM (2011) National registry of myocardial infarction investigators. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation 124(23):2512–2521PubMedCrossRefGoogle Scholar
- 13.Rashid MK, Guron N, Bernick J, Wells GA, Blondeau M, Chong AY, Dick A, Froeschl MP, Glover CA, Hibbert B, Labinaz M, Marquis JF, Osborne C, So DY, Le May MR (2016) Safety and efficacy of a pharmacoinvasive strategy in ST-segment elevation myocardial infarction: a patient population study comparing a pharmacoinvasive strategy with a primary percutaneous coronary intervention strategy within a regional system. JACC Cardiovasc Interv 9(19):2014–2020.PubMedGoogle Scholar
- 20.Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, ESC Scientific Document Group (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119–177PubMedPubMedCentralCrossRefGoogle Scholar
- 21.Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW (2005) The SYNTAX score angiographic tool grading the complexity of coronary artery disease. Eur Intervention 1(2):219–227Google Scholar
- 22.Iber C, Ancoli-Israel S, Chesson A, Quan SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st edn. American Academy of Sleep Medicine, Westchester, ILGoogle Scholar
- 23.Kwon Y, Duprez DA, Jacobs DR, Nagayoshi M, McClelland RL, Shahar E, Budoff M, Redline S, Shea S, Carr JJ, Lutsey PL (2014) Obstructive sleep apnea and progression of coronary artery calcium: the multi-ethnic study of atherosclerosis study. J am heart Assoc 3(5):e001241PubMedPubMedCentralCrossRefGoogle Scholar
- 25.Zakrzewski M, Zakrzewska E, Kiciński P, Przybylska-Kuć S, Dybała A, Myśliński W, Pastryk J, Tomaszewski T, Mosiewicz J (2016) Evaluation of fibrinolytic inhibitors: alpha-2-antiplasmin and plasminogen activator inhibitor 1 in patients with obstructive sleep apnoea. PLoS ONE 11(11):e0166725PubMedPubMedCentralCrossRefGoogle Scholar
- 26.O’Gara PT, Kushner FG, Ascheim DD et al (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (61(4):78–140CrossRefGoogle Scholar
- 29.Hein T, Loo G, Ng WY, Tai BC, Kajiya T, Tan A, Khoo SM, Chan M, Low AF, Chia BL, Richards M, Lee CH (2013) Relationship between apnoea-hypopnoea index and angiographic coronary disease phenotypes in patients presenting with acute myocardial infarction. Acute Card Care 15(2):26–33PubMedCrossRefGoogle Scholar
- 31.Mazza A, Bendini MG, Cristofori M, Nardi S, Leggio M, De Cristofaro R, Giordano A, Cozzari L, Giordano G, Cappato R (2009) Baseline apnoea/hypopnoea index and high-sensitivity C-reactive protein for the risk of recurrence of atrial fibrillation after successful electrical cardioversion: a predictive model based upon the multiple effects of significant variables. Europace 11(7):902–909PubMedCrossRefGoogle Scholar